A detailed history of Pro Share Advisors LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Pro Share Advisors LLC holds 3,424 shares of ASND stock, worth $466,965. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,424
Previous 3,576 4.25%
Holding current value
$466,965
Previous $487,000 4.93%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$113.0 - $153.43 $17,176 - $23,321
-152 Reduced 4.25%
3,424 $511,000
Q2 2024

Aug 13, 2024

SELL
$121.07 - $153.67 $54,360 - $68,997
-449 Reduced 11.16%
3,576 $487,000
Q1 2024

May 08, 2024

BUY
$123.45 - $159.4 $44,565 - $57,543
361 Added 9.85%
4,025 $608,000
Q4 2023

Feb 14, 2024

SELL
$86.1 - $127.36 $5,768 - $8,533
-67 Reduced 1.8%
3,664 $461,000
Q3 2023

Nov 13, 2023

BUY
$86.5 - $103.97 $3,373 - $4,054
39 Added 1.06%
3,731 $349,000
Q2 2023

Aug 10, 2023

SELL
$69.96 - $97.84 $17,909 - $25,047
-256 Reduced 6.48%
3,692 $329,000
Q1 2023

May 11, 2023

SELL
$104.9 - $126.78 $70,387 - $85,069
-671 Reduced 14.53%
3,948 $423,000
Q4 2022

Feb 02, 2023

SELL
$99.42 - $131.97 $4,772 - $6,334
-48 Reduced 1.03%
4,619 $564,000
Q3 2022

Nov 04, 2022

BUY
$84.03 - $110.23 $29,158 - $38,249
347 Added 8.03%
4,667 $482,000
Q2 2022

Aug 01, 2022

SELL
$78.08 - $117.61 $110,717 - $166,770
-1,418 Reduced 24.71%
4,320 $402,000
Q1 2022

May 10, 2022

SELL
$102.18 - $135.75 $209,571 - $278,423
-2,051 Reduced 26.33%
5,738 $673,000
Q4 2021

Feb 08, 2022

SELL
$127.1 - $169.66 $430,741 - $574,977
-3,389 Reduced 30.32%
7,789 $1.05 Million
Q3 2021

Nov 12, 2021

BUY
$112.67 - $176.92 $201,679 - $316,686
1,790 Added 19.07%
11,178 $1.78 Million
Q2 2021

Aug 13, 2021

BUY
$121.62 - $145.29 $263,793 - $315,134
2,169 Added 30.05%
9,388 $1.24 Million
Q1 2021

May 14, 2021

SELL
$124.92 - $173.33 $96,813 - $134,330
-775 Reduced 9.69%
7,219 $930,000
Q4 2020

Feb 09, 2021

BUY
$151.2 - $182.76 $70,156 - $84,800
464 Added 6.16%
7,994 $1.33 Million
Q3 2020

Nov 13, 2020

BUY
$134.29 - $154.32 $20,680 - $23,765
154 Added 2.09%
7,530 $1.16 Million
Q2 2020

Aug 03, 2020

BUY
$110.87 - $156.01 $117,411 - $165,214
1,059 Added 16.76%
7,376 $1.09 Million
Q1 2020

May 15, 2020

SELL
$97.01 - $145.11 $348,750 - $521,670
-3,595 Reduced 36.27%
6,317 $711,000
Q4 2019

Feb 12, 2020

SELL
$91.45 - $139.12 $224,326 - $341,261
-2,453 Reduced 19.84%
9,912 $1.38 Million
Q3 2019

Nov 12, 2019

SELL
$95.8 - $118.9 $75,394 - $93,574
-787 Reduced 5.98%
12,365 $1.19 Million
Q2 2019

Aug 13, 2019

SELL
$107.11 - $132.09 $56,982 - $70,271
-532 Reduced 3.89%
13,152 $1.51 Million
Q1 2019

May 15, 2019

BUY
$62.15 - $129.99 $14,667 - $30,677
236 Added 1.75%
13,684 $1.61 Million
Q4 2018

Feb 14, 2019

SELL
$55.16 - $69.67 $146,504 - $185,043
-2,656 Reduced 16.49%
13,448 $843,000
Q3 2018

Nov 14, 2018

BUY
$63.77 - $76.28 $16,835 - $20,137
264 Added 1.67%
16,104 $1.14 Million
Q2 2018

Aug 13, 2018

BUY
$58.55 - $73.92 $43,912 - $55,440
750 Added 4.97%
15,840 $1.05 Million
Q1 2018

May 14, 2018

SELL
$38.98 - $68.04 $84,196 - $146,966
-2,160 Reduced 12.52%
15,090 $987,000
Q4 2017

Feb 14, 2018

BUY
$31.98 - $40.38 $551,655 - $696,555
17,250
17,250 $691,000

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.61B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.